Von Hippel Lindau/VHL Antibody (G-7): sc-17780

VHL Antibody (G-7) is a mouse monoclonal IgG1 kappa light chain antibody that detects von Hippel-Lindau (VHL) protein of mouse, rat, and human origin through applications such as western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, and ELISA. VHL (G-7) antibody is offered in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase, phycoerythrin, fluorescein isothiocyanate, and multiple Alexa Fluor® conjugates. VHL protein plays a crucial role as a tumor suppressor, and individuals with germline mutations in VHL gene are at a heightened risk for developing several types of tumors, including renal carcinoma, hemangioblastoma of the central nervous system, and pheochromocytoma. One of the key functions of VHL protein is interaction with the Elongin (SIII) complex, which is essential for regulating gene expression. The Elongin complex consists of three subunits: Elongin A, which is transcriptionally active, and two regulatory subunits, Elongin B and Elongin C. VHL binds to Elongin B and C, thereby inhibiting transcriptional activity of the complex, which is vital for maintaining normal cellular functions and preventing tumorigenesis. Additionally, various isoforms of VHL have been identified, resulting from alternative splicing, and molecular weights can differ across species, highlighting the complexity and importance of VHL in cellular regulation and cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Von Hippel Lindau/VHL Antibody (G-7) References:

1. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.  |  Ivan, M., et al. 2001. Science. 292: 464-8. PMID: 11292862
2. TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss.  |  Hu, L., et al. 2020. Cancer Discov. 10: 460-475. PMID: 31810986
3. Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs.  |  Bond, MJ., et al. 2020. ACS Cent Sci. 6: 1367-1375. PMID: 32875077
4. Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules.  |  Nabet, B., et al. 2020. Nat Commun. 11: 4687. PMID: 32948771
5. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.  |  Wang, C., et al. 2022. Eur J Med Chem. 227: 113906. PMID: 34656901
6. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.  |  Diehl, CJ. and Ciulli, A. 2022. Chem Soc Rev. 51: 8216-8257. PMID: 35983982
7. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo.  |  Kofink, C., et al. 2022. Nat Commun. 13: 5969. PMID: 36216795
8. Critical role of VHL/BICD2/STAT1 axis in crystal-associated kidney disease.  |  Hao, W., et al. 2023. Cell Death Dis. 14: 680. PMID: 37833251
9. VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.  |  Wang, Z., et al. 2024. EMBO J. 43: 931-955. PMID: 38360997
10. VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.  |  Wolf, MM., et al. 2024. J Clin Invest. 134: PMID: 38618956

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Von Hippel Lindau/VHL Antibody (G-7) has 20 citations in a variety of scientific publications.

Primary antibodies like Anti-Von Hippel Lindau/VHL Antibody (G-7) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Von Hippel Lindau/VHL Antibody (G-7) Specifications

Alternate Product Name: von Hippel-Lindau tumor suppressor

Product Clone Name: G-7

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-181

Epitope Target: VHL

Epitope Species: mouse

Product Reactivity/Detection: VHL

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 20 citations in various scientific publications

Available Conjugates/Forms for Von Hippel Lindau/VHL Antibody (G-7): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin

The preferred Von Hippel Lindau/VHL antibody is Von Hippel Lindau/VHL Antibody (VHL40): sc-135657.